Anxiety and Related Sleep Disorders - Israel

Revenue in the Anxiety and Related Sleep Disorders market is projected to reach US$50.24m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 0.43%, resulting in a market volume of US$51.34m by 2029.
In global comparison, most revenue will be generated United States (US$3.21bn in 2024).
In relation to total population figures, per person revenues of US$106.90 are generated in 2024.

The Anxiety and Related Sleep Disorders market covers sales of three drug classes: anxiolytics, hypnotics, and sedatives. These classes contain different types of drugs, such as benzodiazepines, anticonvulsants, and antihistamines, that reduce anxiety and insomnia symptoms caused by anxiety. These medications mainly fall into the category of prescription drugs.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Pfizer, Bristol-Myers Squibb, GlaxoSmithKline PLC, Johnson & Johnson, and Merck & Co.

Pharmaceutical sales and consumption of anxiolytics
Pharmaceutical sales and consumption hypnotics and sedatives

Non-mental health related sleep disorders
Any other anxiety medications
Psychotherapy

The Anxiety and Related Sleep Disorders market in Israel is experiencing significant growth due to several factors.

Customer preferences: Customers in Israel are increasingly seeking solutions for managing anxiety and sleep disorders. This is driven by the growing awareness of mental health issues and the importance of a good night's sleep for overall well-being. As a result, there is a rising demand for products and services that address these concerns, such as pharmaceuticals, therapy, and alternative treatments.

Trends in the market: One of the key trends in the Anxiety and Related Sleep Disorders market in Israel is the increasing adoption of digital solutions. Mobile applications and online platforms that offer therapy, meditation, and sleep tracking have gained popularity among Israeli consumers. These digital solutions provide convenience and accessibility, allowing individuals to manage their anxiety and sleep disorders from the comfort of their own homes.Another trend in the market is the growing interest in natural and alternative remedies. Many consumers in Israel are seeking non-pharmaceutical options for managing anxiety and sleep disorders, such as herbal supplements, acupuncture, and aromatherapy. This trend is driven by a desire for more holistic and personalized approaches to healthcare.

Local special circumstances: Israel has a high prevalence of anxiety and sleep disorders compared to other countries. This can be attributed to various factors, including a stressful work culture, military service obligations, and a high cost of living. The unique socio-cultural context of Israel creates a fertile ground for the development of the Anxiety and Related Sleep Disorders market.

Underlying macroeconomic factors: Israel has a strong economy with a high level of innovation and technological advancement. This provides a favorable environment for the growth of the Anxiety and Related Sleep Disorders market, as it allows for the development of cutting-edge pharmaceuticals, devices, and digital solutions. Additionally, the Israeli government has recognized the importance of mental health and has implemented policies to support research and development in this field.In conclusion, the Anxiety and Related Sleep Disorders market in Israel is growing due to increasing customer preferences for managing anxiety and sleep disorders, the adoption of digital solutions, the interest in natural and alternative remedies, local special circumstances, and underlying macroeconomic factors. This market is expected to continue expanding as the demand for mental health solutions continues to rise in Israel.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.